This week, five Biotechnology stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).
This week, Insmed Inc. (NASDAQ:INSM) is showing significant improvement as the company’s rating hops from a C (“hold”) to a B (“buy”). Insmed develops and commercializes drugs that treat metabolic diseases, endocrine disorders and oncology. For more information, get Portfolio Grader’s complete analysis of INSM stock.
The rating of Ariad Pharmaceuticals (NASDAQ:ARIA) moves up this week, rising from a C to a B. ARIAD Pharmaceuticals is an oncology company that focuses on the discovery, development, and commercialization of medicines for cancer patients. The stock price has risen 5.7% over the past month, better than the 3% increase the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of ARIA stock.
Neurocrine Biosciences (NASDAQ:NBIX) improves from a C to a B rating this week. Neurocrine Biosciences is focused on the discovery and development of therapeutics for neuropsychiatric, neuroinflammatory, and neurodegenerative diseases and disorders. For more information, get Portfolio Grader’s complete analysis of NBIX stock.
Array BioPharma (NASDAQ:ARRY) boosts its rating from a C to a B this week. Array BioPharma is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. Wall Street has pushed the stock higher by 7% over the past month. For more information, get Portfolio Grader’s complete analysis of ARRY stock.
Celldex Therapeutics (NASDAQ:CLDX) is progressing from last week’s rating of B (“buy”) as the company improves to an A (“strong buy”) this week. Celldex Therapeutics is engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. Wall Street seems to agree with the upgrade and has propelled the stock up 37.4% over the past month. For more information, get Portfolio Grader’s complete analysis of CLDX stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
